NMRA Stock News & Analysis | Latest Updates

Neumora Therapeutics to Participate in Upcoming Conferences in September

(NASDAQ:NMRA) WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in three investor conferences in September.

September 2, 2025Events

NMRA News

Neumora Therapeutics to Participate in Upcoming Conferences in September

On May 14, Neumora Therapeutics Received Nasdaq Non-Compliance Notice

Needham Reiterates Buy on Neumora Therapeutics, Maintains $5 Price Target

Neumora Therapeutics Q1 EPS $(0.42) Misses $(0.38) Estimate

Needham Reiterates Buy on Neumora Therapeutics, Maintains $5 Price Target

B of A Securities Downgrades Neumora Therapeutics to Underperform, Lowers Price Target to $1

Guggenheim Downgrades Neumora Therapeutics to Neutral

Stifel Downgrades Neumora Therapeutics to Hold, Lowers Price Target to $2

HC Wainwright & Co. Reiterates Buy on Neumora Therapeutics, Maintains $18 Price Target

RBC Capital Reiterates Sector Perform on Neumora Therapeutics, Maintains $4 Price Target

Needham Reiterates Buy on Neumora Therapeutics, Maintains $5 Price Target

HC Wainwright & Co. Maintains Buy on Neumora Therapeutics, Lowers Price Target to $18

Neumora Therapeutics Q4 2024 GAAP EPS $(0.37) Beats $(0.45) Estimate, Cash Balance Of $307.6M

HC Wainwright & Co. Reiterates Buy on Neumora Therapeutics, Maintains $30 Price Target

Neumora Therapeutics Announced That Effective February 14, Paul Berns, Neumora's Co-founder And Executive Chair Of The Board Of Directors, Will Transition To CEO And Chairman, And Henry Gosebruch Will Step Down, Michael Milligan Will Serve As CFO

JP Morgan Downgrades Neumora Therapeutics to Neutral, Lowers Price Target to $15